AUGMENT:来那度胺联合利妥昔单抗对比安慰剂联合利妥昔单抗治疗复发或难治性惰性淋巴瘤的III期研究
AUGMENT是一项III期多中心随机试验,纳入358例复发和/或难治性滤泡性或边缘区淋巴瘤患者,比较来那度胺联合利妥昔单抗与安慰剂联合利妥昔单抗。来那度胺联合利妥昔单抗组无进展生存期显著改善,风险比为0.46(95%CI 0.34-0.62;P<.001),中位无进展生存期39.4个月 vs 14.1个月。来那度胺联合利妥昔单抗组感染、中性粒细胞减少和皮肤反应更常见。
要点
- 来那度胺联合利妥昔单抗较安慰剂联合利妥昔单抗显著改善复发/难治性惰性淋巴瘤的无进展生存期。
- 来那度胺联合利妥昔单抗组3/4级中性粒细胞减少发生率为50% vs 13%,高于安慰剂联合利妥昔单抗组。
- 来那度胺联合利妥昔单抗组感染发生率为63% vs 49%,皮肤反应为32% vs 12%。
核心结论
- 来那度胺联合利妥昔单抗改善了复发惰性淋巴瘤患者中利妥昔单抗的疗效,且安全性可接受。
研究设计与样本
- III期、多中心、随机试验,纳入复发和/或难治性滤泡性或边缘区淋巴瘤患者。
- 患者随机接受来那度胺联合利妥昔单抗(n=178)或安慰剂联合利妥昔单抗(n=180),共358例。
- 来那度胺或安慰剂给药12个周期,利妥昔单抗在第1周期每周一次共4周,第2至5周期第1天给药。
- 主要终点为独立放射学审查的无进展生存期。
主要发现
- 来那度胺联合利妥昔单抗组感染发生率63% vs 安慰剂联合利妥昔单抗组49%。
- 来那度胺联合利妥昔单抗组中性粒细胞减少发生率58% vs 安慰剂联合利妥昔单抗组23%。
- 来那度胺联合利妥昔单抗组皮肤反应发生率32% vs 安慰剂联合利妥昔单抗组12%。
- 来那度胺联合利妥昔单抗组3或4级中性粒细胞减少发生率50% vs 安慰剂联合利妥昔单抗组13%;3或4级白细胞减少发生率7% vs 2%。
- 来那度胺联合利妥昔单抗组无进展生存期显著优于安慰剂联合利妥昔单抗组,风险比为0.46(95%CI 0.34-0.62;P<.001),中位无进展生存期分别为39.4个月(95%CI 22.9个月至未达到) vs 14.1个月(95%CI 11.4-16.7个月)。
关键数值与推荐
- 来那度胺联合利妥昔单抗组较安慰剂联合利妥昔单抗组无进展生存期风险比为0.46(95%CI 0.34-0.62;P<.001)。
- 来那度胺联合利妥昔单抗组中位无进展生存期39.4个月(95%CI 22.9个月至未达到),安慰剂联合利妥昔单抗组14.1个月(95%CI 11.4-16.7个月)。
- 来那度胺联合利妥昔单抗组3或4级中性粒细胞减少发生率50%,安慰剂联合利妥昔单抗组13%。
- 来那度胺联合利妥昔单抗组3或4级白细胞减少发生率7%,安慰剂联合利妥昔单抗组2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with indolent non-Hodgkin lymphoma typically respond well to first-line immunochemotherapy. At relapse, single-agent rituximab is commonly administered. Data suggest the immunomodulatory agent lenalidomide could increase the activity of rituximab. METHODS: A phase III, multicenter, randomized trial of lenalidomide plus rituximab versus placebo plus rituximab was conducted in patients with relapsed and/or refractory follicular or marginal zone lymphoma. Patients received lenalidomide or placebo for 12 cycles plus rituximab once per week for 4 weeks in cycle 1 and day 1 of cycles 2 through 5. The primary end point was progression-free survival per independent radiology review. RESULTS: A total of 358 patients were randomly assigned to lenalidomide plus rituximab (n = 178) or placebo plus rituximab (n = 180). Infections (63% v 49%), neutropenia (58% v 23%), and cutaneous reactions (32% v 12%) were more common with lenalidomide plus rituximab. Grade 3 or 4 neutropenia (50% v 13%) and leukopenia (7% v 2%) were higher with lenalidomide plus rituximab; no other grade 3 or 4 adverse event differed by 5% or more between groups. Progression-free survival was significantly improved for lenalidomide plus rituximab versus placebo plus rituximab, with a hazard ratio of 0.46 (95% CI, 0.34 to 0.62; P < .001) and median duration of 39.4 months (95% CI, 22.9 months to not reached) versus 14.1 months (95% CI, 11.4 to 16.7 months), respectively. CONCLUSION: Lenalidomide improved efficacy of rituximab in patients with recurrent indolent lymphoma, with an acceptable safety profile.
引用
- Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2019. PMID: 30897038. doi:10.1200/JCO.19.00010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。